Aeterna Zentaris Inc.’s conference call with investors on the phase III failure of Zoptrex (zoptarelin doxorubicin) in endometrial cancer ended quickly and the company put off until its first-quarter earnings report next Tuesday details about what the blowup means for the company’s future.